1066P Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC)
Asaad Trabolsi(University of Miami), G. Lopes(University of Miami), Estelamari Rodríguez(University of Miami), Hirva Mamdani(Wayne State University), Jesús Antonio Ocejo Gallegos(Jackson Memorial Hospital), B. Halmos(Albert Einstein College of Medicine), Stephen V. Liu(Georgetown University), Sonam Puri(University of Utah), Misako Nagasaka(University of California, Irvine), Phillip Walker(Caris Life Sciences (United States)), Jorge J. Nieva(University of Southern California), Jun‐Jie Yin(Shanghai University of Traditional Chinese Medicine), Samuel A. Kareff(University of Miami), Chadi Nabhan(University of Chicago), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530